1. Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway
   Na Li et al, 2021, World Journal of Gastrointestinal Oncology CrossRef
2. Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1α Protein Synthesis via AKT/mTOR Pathway
   Jingyi Luo et al, 2021, International Journal of Molecular Sciences CrossRef
3. Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential
   Min Sun et al, 2024, Frontiers in Pharmacology CrossRef
4. Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review
   Kristy T. K. Lau et al, 2021, Reviews in Endocrine and Metabolic Disorders CrossRef
5. Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice
   Jessica M. Snyder et al, 2023, GeroScience CrossRef
6. Comparison between sodium‐glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real‐world evidence study
   Hui‐Lin Sung et al, 2024, Diabetes/Metabolism Research and Reviews CrossRef
7. The role of metabolic reprogramming in pancreatic cancer chemoresistance
   Chang Liu et al, 2023, Frontiers in Pharmacology CrossRef
8. Diabetes and pancreatic cancer: Exploring the two-way traffic
   Ayan Roy et al, 2021, World Journal of Gastroenterology CrossRef
9. Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK
   Kenji Shoda et al, 2023, Cellular and Molecular Neurobiology CrossRef